Last updated on Apr 23, 2014 3:59 PM ET
|NASDAQ : SPHS||3.41||
Sophiris Bio Inc. (NASDAQ: SPHS) is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied market with significant market potential. Sophiris’ lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris is currently enrolling patients in the PLUS 1 Phase III clinical study using PRX302 for the treatment of symptoms of BPH.